+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating two new treatments compared to the best standard care for men with prostate cancer that has spread to other parts of the body and still responds to hormone therapy. This phase 3 trial includes multiple hospitals across the UK and is led by University College London. The study aims to see if adding targeted radiotherapy or a radioactive drug can slow cancer spread and improve survival. Participants are assigned by computer to one of several groups. One group receives standard care, which includes androgen deprivation therapy ADT plus other hormone therapies, possible chemotherapy with docetaxel, and local radiotherapy. Another group receives standard care plus targeted high-dose radiotherapy SABR to metastatic sites. A third group receives standard care plus a radioactive therapy called 177Lu-PSMA-617, given in cycles with two doses per cycle. Treatments continue unless side effects are severe or participants choose to stop. During the study, participants will have scans and tests to monitor their cancer and side effects. Doctors will check safety and treatment adherence over time. Researchers will measure overall survival, failure-free survival, progression-free survival, prostate cancer-specific survival, and quality of life up to 10 years from randomization. Safety will be closely monitored, and participants health will be followed during and after treatment.

Age: 18Years +MALEPhase 3
18 locations
R

Actively Recruiting

Researchers are studying brenipatide LY3537031 to evaluate its safety, side effects, and effectiveness in adults with Irritable Bowel Syndrome-Constipation IBS-C. The study compares brenipatide given by injection under the skin to a placebo in a phase 2 clinical trial. Participants must meet specific IBS-C criteria and have significant abdominal pain to join. Participants receive the study drug or placebo through subcutaneous injection. The trial lasts about 36 weeks, with treatment and monitoring occurring during this period. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will keep a daily diary to track symptoms like abdominal pain and bowel movements. Researchers will measure the percentage of weeks participants respond to treatment based on clinical criteria between weeks 9 and 16. Safety and side effects will also be closely monitored throughout the trial.

Age: 18Years - 75YearsAll GendersPhase 2
70 locations
E

Actively Recruiting

Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. This study compares brenipatide given under the skin to a placebo and aims to understand how well the drug is tolerated and how it impacts symptoms in participants aged 18 to 75. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Eli Lilly and Company. Participants receive either brenipatide or placebo, both administered subcutaneously. The study follows a parallel design where different groups receive either the experimental drug or the placebo. Treatment and evaluation last approximately 36 weeks, with key outcome measurements focused on symptom responses between weeks 9 to 16 and up to week 24. During the study, participants will record symptoms daily in an electronic diary, including abdominal pain and stool consistency. Researchers will monitor safety, side effects, and symptom changes through these reports and scheduled assessments. The main outcome is the percentage of days participants show significant symptom improvement during the critical weeks of treatment. The study includes a full follow-up period to assess lasting effects and safety throughout the 36 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
89 locations
P

Actively Recruiting

This research aims to evaluate the long-term safety of luspatercept in participants who have previously taken part in other luspatercept clinical trials for conditions such as Myelodysplastic Syndromes MDS, Beta-thalassemia, and Myeloproliferative Neoplasm-associated Myelofibrosis. It is a Phase 3b, open-label, single-arm rollover study designed to continue monitoring participants who tolerated previous luspatercept treatment and may benefit from ongoing therapy, as well as those in post-treatment follow-up phases. Participants transitioning from prior luspatercept studies will enter a Transition Phase defined by an enrollment visit. Those continuing treatment will receive luspatercept injections subcutaneously at the same dose and schedule as their parent trial, administered by study staff at clinical sites. The study includes a Treatment Phase for ongoing luspatercept administration and a Follow-up Phase comprising a 42-day safety follow-up after the last dose and a long-term post-treatment follow-up phase lasting at least 5 years to monitor overall survival and progression to malignancies. Throughout the study, participants will be regularly assessed for adverse events, progression to high-risk MDS or AML, and development of other malignancies or treatment-related masses. Safety parameters are evaluated during the 42-day follow-up, while long-term survival and disease progression are monitored every six months for at least five years. The study will conclude when all participants have completed five years of combined treatment and follow-up.

Age: 18Years +All GendersPhase 3
143 locations
A

Actively Recruiting

Researchers are evaluating whether apixaban, an oral anticoagulant tablet, can reduce blood clots in people with lung cancer who are receiving chemotherapy or similar systemic anticancer treatments. Venous thromboembolism VTE is a common and serious complication in lung cancer patients undergoing such therapies, leading to poorer quality of life, higher healthcare costs, and increased morbidity and mortality. Current standard care does not routinely use blood thinners for outpatients receiving systemic anticancer therapy, and this trial aims to address that gap. Participants will be randomly assigned to receive either apixaban 2.5 mg tablets or a matching placebo, taken twice daily by mouth for six months alongside their cancer treatments. This phase 3, multicenter, double-blind, placebo-controlled trial will compare these two groups to assess if apixaban reduces the rate of VTE. The trial includes a total of 1456 patients recruited over 36 months with a follow-up period of 6 months for primary outcome measurement. During the trial, participants will be asked to take the study medication as directed and complete diaries recording treatment adherence. They will also complete quality of life and health resource use questionnaires. Researchers will monitor for blood clots confirmed by objective testing, bleeding events, survival outcomes, and patient-reported quality of life over six months. Female participants who can become pregnant are required to use effective contraception during and shortly after treatment. The studys total duration, including setup and analysis, is planned for 60 months.

Age: 16Years +All GendersPhase 3
8 locations
P

Actively Recruiting

Researchers are conducting an international, multicenter, prospective, non-randomized observational study to confirm and support the clinical safety and performance of the Coroflex ISAR NEO coronary stent system. This study focuses on patients with coronary artery disease CAD or ischemic heart disease treated in real-world clinical settings to meet European Union Medical Device Regulation requirements for post-market follow-up. It involves consecutive patients treated with the sirolimus-eluting Coroflex ISAR NEO stent as intended by the manufacturer. Participants receive the Coroflex ISAR NEO coronary stent system during their routine percutaneous coronary intervention PCI procedures. This study observes patients undergoing stent placement according to standard clinical recommendations, without randomization or specific treatment assignment. The study includes patients with new lesion lengths between 2 and 4 mm and follows them after stent implantation to monitor outcomes and device performance. During the study, participants are monitored for safety and effectiveness outcomes including freedom from target lesion failure within seven days after the procedure. Additional assessments track potential complications during PCI such as accidental stent dislodgement, balloon or hypotube rupture, coronary perforation, dissection, no reflow, and thrombosis. Data collection continues according to clinical practice, with informed consent obtained and follow-up lasting up to the study completion date in February 2027.

Age: 18Years +All Genders
26 locations
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations
S

Actively Recruiting

This research is focused on people with type 1 diabetes who also have symptoms of heart failure, a condition that can cause breathlessness, tiredness, and swelling. The study aims to find out if sotagliflozin, a tablet medication, can improve quality of life and heart failure symptoms for these individuals. While sotagliflozin has shown benefits in people with type 2 diabetes and heart failure, its effects on those with type 1 diabetes are not yet known. Participants will be randomly assigned to receive either sotagliflozin tablets or placebo tablets, which look identical but contain no active medicine. They will take one tablet daily for 16 weeks. This is a double-blind trial, meaning neither the researchers nor participants will know which treatment is being taken until the study ends. The trial will last about 6 months per participant, with the entire study expected to run for about 26 months. During the study, participants will have their heart failure symptoms and quality of life assessed using questionnaires like the Kansas City Cardiomyopathy Questionnaire KCCQ. Other evaluations include walking tests, blood tests for heart and diabetes markers, and monitoring for safety concerns like low blood sugar or diabetic ketoacidosis. The study will measure changes in these outcomes from the start to week 16, with ongoing safety follow-up until week 20.

Age: 18Years - 84YearsAll GendersPhase 2
17 locations
T

Actively Recruiting

Chronic obstructive pulmonary disease COPD is a common lung condition affecting many adults worldwide, with exacerbations leading to worsening health and hospital admissions. This trial focuses on patients recently discharged after a hospital stay for a COPD exacerbation, aiming to reduce the risk of readmission and improve outcomes during the critical 90-day high-risk period after discharge. The study is a phase 3, multicenter randomized controlled trial addressing an important healthcare challenge and potential cost savings for the NHS. The trial compares a supported rescue pack management plan to standard care. Participants in the supported rescue pack group receive a 5-day rescue pack of prednisolone and antibiotics, a written self-management plan based on the Asthma-Lung UK plan, and twice-weekly automated phone or text symptom assessments for 90 days. Those in the standard care group do not receive rescue packs on discharge but may access them through community care. The trial will monitor the use of rescue packs and support provided during the 90-day period. Participants will be involved in regular symptom monitoring through automated calls or texts and follow-up assessments. Researchers will measure time to first hospital readmission within 90 days as the primary outcome, along with secondary outcomes including readmission frequency, days alive and out of hospital, corticosteroid and antibiotic use, healthcare contacts, quality of life, and cost-effectiveness. Safety monitoring will include adverse events and antimicrobial resistance over an average of 4 years, with participant involvement lasting up to one year for some assessments.

Age: 40Years +All GendersPhase 3
34 locations
P

Actively Recruiting

The trial investigates the role of ixazomib in patients with relapsed multiple myeloma who have previously undergone autologous stem cell transplant ASCT. It is a phase III, randomized, controlled, multi-center, open-label study aiming to assess whether adding a proteasome inhibitor to salvage ASCT conditioning improves depth of response and how consolidation and maintenance therapy influence the durability of response. The study also evaluates overall survival, progression-free survival, response rates, minimal residual disease, toxicity, and quality of life. Participants first receive re-induction therapy with 4 to 6 cycles of ixazomib, thalidomide, and dexamethasone ITD, each cycle lasting 28 days. Those achieving at least stable disease are randomly assigned to receive either conventional ASCT using melphalan alone or augmented ASCT combining melphalan with ixazomib. After ASCT, participants with minimal response or better are further randomized to either receive consolidation with 2 cycles of ITD followed by ixazomib maintenance until disease progression or no further treatment. During the study, participants undergo regular assessments including response evaluation 100 days post-ASCT, monitoring of progression-free survival for up to 120 months, and measurement of minimal residual disease at several time points. Safety and toxicity are closely monitored throughout re-induction, post-ASCT, consolidation, and maintenance phases. Quality of life questionnaires are completed at baseline, post-re-induction, post-ASCT, and during follow-up visits up to 24 months. The study plans to register 406 participants, with 284 randomized at the first stage and 248 at the second stage.

Age: 18Years +All GendersPhase 3
91 locations

1-10 of 12

1